Assenagon Asset Management’s Burning Rock Biotech BNR Stock Holding History

Assenagon Asset Management’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,425	Closed	-$771K	–	1342
2023 Q1	$771K	Sell	27,425 -7,908	-22%	-$237K	﹤0.01%	1120
2022 Q4	$795K	Sell	35,333 -123	-0.3%	-$2.81K	﹤0.01%	1091
2022 Q3	$847K	Sell	35,456 -8,220	-19%	-$265K	﹤0.01%	968
2022 Q2	$1.27M	Buy	+43,676	New	+$1.95M	﹤0.01%	1001
2021 Q4	–	Sell	-6,117	Closed	-$1.09M	–	1433
2021 Q3	$1.09M	Buy	+6,117	New	+$1.36M	﹤0.01%	882

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management's BNR Position: Q2 2023 in Review

Assenagon Asset Management sold out of Burning Rock Biotech (BNR) in Q2 2023, closing a stake of 27,425 shares — an estimated $771K sold.

Assenagon Asset Management first reported a position in BNR in Q3 2021 and held it in 5 quarters. The position peaked at $1.27M in Q2 2022. 32 funds tracked by Wall St. Rank hold BNR as of Q2 2023.

Assenagon Asset Management reported no remaining Burning Rock Biotech position as of Q2 2023 after selling out during the quarter.
Assenagon Asset Management sold 27,425 Burning Rock Biotech shares in Q2 2023, an estimated $771K.
Assenagon Asset Management first reported a position in Burning Rock Biotech in Q3 2021 and held it in 5 quarters.
Assenagon Asset Management's Burning Rock Biotech position peaked at $1.27M in Q2 2022.
32 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2023.

Based on Assenagon Asset Management's 13F filing for Q2 2023, filed 25 Jul 2023.